Breast cancer remains a leading cause of female morbidity and mortality worldwide [1] . Several Received: July 16, 2008; Accepted: February 17, 2009 (9 of 1.30 (0.20-8.50; P ϭ 0.78), respectively. In lymph node-positive breast cancer patients, the RRs for ; P Ͻ 0.0001) and 1.49 (0.80-2.77; P ϭ 0.21), respectively. This meta-analysis indicates that reduced p27 is an independent prognostic factor for poor overall and disease-free cancer survival.
clinically relevant prognostic marker for breast cancer. A metaanalysis confirming the independent prognostic value of p27 would support further prospective analyses of p27 in the context of clinical trials in which patients received uniform treatment.
To investigate whether p27 is indeed a prognostic factor in breast cancer, we conducted a systematic review of the published literature. In an attempt to review those data quantitatively, we used a meta-analysis to gain insights into whether p27 could provide useful guidance in the management of breast cancer.
Materials and methods

Search strategy and selection criteria
We performed this meta-analysis according to a predetermined written protocol of our group. To be eligible for inclusion in our meta-analysis, studies had to be English- 
Data extraction and handling
Data were extracted in an Access database by two investigators (R.X. and J.B.) trained to interpret information to ensure homogeneity in data gathering and entry. Reviews, non-original articles and studies on breast cancer cell lines and animal models were excluded from our review. To assess the effect of subjectivity and potential systematic biases on data gathering, these investigators extracted data from eligible studies independently and reached consensus on all items. Complete concordance was reached for all main variables assessed in this analysis. To avoid duplicate data, we identified articles that included the same cohort of patients by reviewing interstudy similarities in the country in which the studies were done, investigators in the studies
Results
The results of the search strategy for studies are summarized in Fig. 1 [ [4] [5] [6] [7] [8] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Fig. 2A) .
Among all the studies in our review, the population sample of Porter and coworkers [36] which included a total of 2031 cases and accounted for 31.42% of all 6463 cases combined from the [40] . Clinically, it is crucial to identify those patients who would benefit from adjuvant chemotherapy by appropriate prognostic markers. Many studies have indicated that changes in p27 expression in breast cancer can be used to predict survival and response to chemotherapy [4] [5] [6] [7] [8] [9] [10] , and many observational studies have concluded that p27 is a prognostic factor in breast cancer [4] [5] [6] , whereas other studies suggested a relationship between p27 and outcome but fell short of statistical significance [7] [8] [9] . To determine whether p27 can serve as a prognostic factor in breast cancer, we undertook a systematic review of the literature with a meta-analysis.
Discussion
Conventional prognostic factors such as tumour stage, grade, size and multifocality do not accurately predict the clinical outcome in many patients with breast cancer [39]; thus, the search for better prognostic indicators and new predictors is of utmost importance
In the articles reviewed in our meta-analysis, we found that the prognostic significance of p27 varied substantially among studies.
Catzavetos and colleagues reported that low (Ͻ50%) levels of p27 correlated with decreased DFS but not with OS in a multivariate
analysis [4] . Tan and colleagues reported that T1a and T1b breast carcinoma lacking p27 expression were associated with lower OS in a multivariate analysis [5] . Using univariate and multivariate analyses, Wu and coworkers noted a prognostic significance of p27 for OS and DFS in both node-negative and node-positive breast cancer [26] . In contrast, Barbareschi and coworkers reported that p27 expression did not predict outcome in their whole series of cases but that high p27 expression indicated a poor prognosis even in node-negative cases [27] . Our meta-analysis results showed that reduced levels of p27 appear to be an independent prognostic factor for breast cancer as indicated by OS ( Fig. 2A) and DFS (Fig. 2B) but not by RFS (Fig. 2C) . Ideally, a strong prognostic role needs to be supported by high RR with low P-value. Some researchers even suggested that prognostic factor that has an RR Ͻ 2 could be of limited practical use [41, 42] [43] . For example, different antibodies used and different cut-off values (Table 2) were used in the studies included in this metaanalysis. Among the eligible studies, three independent studies (n ϭ 576) included only patients with lymph node-negative disease [32, 33, 37] , and the length of median follow-up in the studies varied substantially (from 72.3 months in the studies of Tan and colleagues to 21.5 years in the reports of Gillett and coworkers [5, 7] [45] . Although intracellular concentration as well as sub-cellular localization would change the function of p27 in tumour cells [46] , most studies that we reviewed (except for two [30, 37] ) did not investigate the correlation of cytoplasmic and nuclear expression of p27 with clinical outcome in breast cancer simultaneously. One of the reviewed studies reported that cytoplasmic p27 had previously been correlated with a poor patient prognosis [30] and that further studies were needed to verify that conclusion.
Screening p27 residues identified many potential phosphorylation sites. It has been demonstrated that phosphorylation controls the stability and expression of p27 [47, 48] 
